Aptar Pharma Acquires Device Technology Assets of SipNose

Aptar Pharma announces that it has acquired all device technology assets from the proprietary portfolio of SipNose Nasal Delivery Systems, a company focused on intranasal delivery platforms for local, systemic and central nervous system indications.

SipNose offers a variety of devices that are designed and adapted to fit a wide range of therapies and offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.

SipNose’s expanded innovative delivery systems, which include liquid and dry powder intranasal delivery, will further strengthen Aptar Pharma’s nose-to-brain pathway expertise and fuel additional development and new scientific research.
more at: https://aptar.com/news-events/aptar-pharma-acquires-device-technology-assets-of-sipnose/

Back To Top
×Close search
Search